DESIGN AND CHARACTERIZATION OF AZILSARTAN DRUG LOADED NANOPARTICLES

Shaik Harun Rasheed[1], M. Radhika Reddy[2*], K. Mallikarjuna Reddy[3], K. Ramakrishna[4], CH. Srinivas Reddy[5], Ahemadi Banu[6]

Abstract

Azilsartan is an AT1 receptor selective blocker., strongly fixes to the AT1 receptor and then progressively separates from it. This prevents angiotensin II from binding, Aldosterone actions are diminished and vasodilation is produced. The objective of this work was to use polymer to create a nanoparticulate drug delivery system for the hypertension medication Azilsartan (poly vinyl alcohol). The produced loading of the formulation effectiveness, entrapment effectiveness, Zeta potential, particle size distribution, and drug polymer compatibility. The improved formulation F7 (drug 50 mg, polyvinyl alcohol 75 mg, 10 mg cyclodextin) had an entrapment efficiency of 99.38 ± 0.08 and a 24-hour *in-vitro* drug release of 98.46%. The diffusion and erosion mechanisms of release are likewise followed, and it also obeys the zero order. Lrbesartan nanoparticles were determined to be in the optimal range of surface shape and to be in the average nanometer range (358.4 nm) in the optimised formulation (F7), according to surface morphology. According to the results of the stability test, the formulation (F7characteristics)'s did not alter. Zeta potential measurements on the improved formulation (F7) were also looked at.

Keywords: Azilsartan, nanoparticles, optimization, and drug release.

[1,3,4,5]Department of Pharmaceutics, Guru Nanak Institutions Technical Campus - School of Pharmacy, Khanapur, Ibrahimpatnam, Rangareddy, Telangana – 501506, India.
[2*]Associate Professor, Department of Pharmaceutics, Guru Nanak Institutions Technical Campus - School of Pharmacy, Mobile: +91-9704246358, Email: principal.gnip@gniindia.org
[6]Department of Pharmacology, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Telangana -502313, India.

***Corresponding Author:** M.Radhika Reddy
*Associate Professor, Department of Pharmaceutics, Guru Nanak Institutions Technical Campus - School of Pharmacy, Mobile: +91-9704246358, Email: principal.gnip@gniindia.org

DOI: - 10.31838/ecb/2023.12.si5.074

Introduction

A specific blocker of AT1 receptors, azilsartan, attaches firmly and slowly dissolved (1) to prevent angiotensin II from binding, which reduces the effects of aldosterone and causes vasodilation (2,3). The prodrug azilsartan medoxomil is metabolised in the gut to the active ingredient azilsartan, was created by For hypertension, Takeda Global Research & Development has developed a drug that has been approved for use in Japan. treatment in 2012. Azilsartan has a 60% absolute bioavailability owing to CYP2C9's first pass metabolism and an 11-hour elimination half-life (2). Azilsartan is categorised as a class II biopharmaceutical in the BCS. The high permeability and low solubility (4.28 x 10^{-3} mg/L) in water at 25 °C make it a poor solvent. (4) make the drug appealing for solubility enhancement techniques since azilsartan absorption depends on the rate at which its dissolution occurs.

For improved water solubility of azilsartan, a variety of techniques have been used, includes liquid-solid compact and solid dispersion (5,6) (7). the most often used kind of advanced instruments for increasing solubility; Drugs medicinal effectiveness has been improved with their help, and their side effects mitigated. Nanocarriers are defined as dispersions or solid particles having at least one dimension between 10 and 1000 nm, and they serve as a transporter module for different particles, such as medicines, by dissolving, entrapping, encapsulating, or connecting the drug to the nanocarrier (8,9). Biocompatible inorganic nanoparticles incorporate metal (gold, copper, silver, iron), metal oxide (iron oxide, zinc oxide), and quantum dots (cadmium selenide and cadmium sulphide). Possible medical applications include medication delivery systems (10,11).

EXPERIMENTAL INVESTIGATION\ AZILSARTAN STANDARD GRAPH CONSTRUCTION

UV Spectroscopy Method

Azilsartan has a spectrophotometric estimate of 220 nm and conforms to Beer-Law Lambert's at concentrations of 5 to 50 mcg/ml.



Fig: 1 STANDARD CURVE FOR AZILSARTAN

STUDY OF PREFORMULATION

IR studies:

Utilizing IR spectroscopy, the unadulterated medication was recognized. IR spectroscopy (utilizing Perkin Elmer) utilizing KBr pellet method did taking drugs. They are squashed in a water driven press at 15 tons of strain to make a clear pellet. On a spectrophometer, the molecule was checked from 4000-400cm-1, and the resultant pinnacles were identified.

METHOD OF PREPARATION OF AZILSARTAN NANOPARTICLE NANO-PRECIPITATION METHOD:

The process of nanoprecipitation was used to create all batches of nanoparticles. The needed amount of medication and polymer were both dissolved in 3 ml of ethanol before being combined with the addition of -cyclodextrin. The last volume of the arrangement was 10ml after the mixer had been homogenized in a vortex mixture for 1 minute. After that, this preparation was centrifuged for 30

minutes at 15000 rpm at 4ºC. The precipitate was washed 3 times by using normal distilled water after the supernatant was discarded. The resulting nanoparticles were desiccated and they were dried through whole night at 60ºC. The produced formulation is then evaluated for drug polymer compatibility tests, zeta potential, particle size, particle size distribution, loading efficiency, entrapment efficiency, and particle size.

Table: 1 Nanoparticles - composition

FORMULATION CODE	DRUG (Azilsartan) mg	PAV (mg)	B CYCLODEXTRIN
NP-F1	50.0	25.0	5.00
NP-F2	50.0	50.0	5.00
NP-F3	50.0	75.0	5.00
NP-F4	50.0	100	5.00
NP-F5	50.0	25.0	10.00
NP-F6	50.0	50.0	10.00
NP-F7	50.0	75.0	10.00
NP-F8	50.0	100	10.00
NP-F9	50.0	25.0	15.00
NP-F10	50.0	50.0	15.00

EVALUATIONOF NANOPARTICLES
DRUG ENTRAPMENT STUDY

Free medication content in the supernatant created in the wake of centrifuging the strong lipid arrangement at decided the ensnarement proficiency examination (15,000rpm for 20 min at zero utilizing ultra axis) UV Spectrophotometric estimation of the absorbance is recoreded at 220 nm.

***IN-VITRO* DRUG RELESE STUDIES**
UV Spectrophotometric Method:

The diffusion membrane method was used to conduct the *in-vitro* drug release evaluation. The prepared the nanoparticles were placed in a dialysis film and filled a measuring cylinder with 200 ml of dispersion medium (phosphate saline pH 7.4). Then the medium was swirled magnetically at constant speed while being kept at 37º C. Every hour, at a predetermined interval, 1 ml of the diffusion media was sampled and replaced with 1 millilitre of new medium. This procedure took place for 24 hours. At220 nm, the sample underwent UV spectrometric measurement. The alignment chart was utilized to decide the extent of medicine delivered at various time stretches.

SCANNING ELECTRON MICROSCOPY

Scanning electron microscopy was utilized to morphologically describe the improved formulation (SEM). Utilizing a cement, small example that was put straightforwardly in Scotch twofold sticky tape, the example for SEM assessment was mounted in the example. The material was examined in a 15 KV scanning electron microscope, and a picture was captured.

SURFACE CHARGE (ZETA POTENTIAL DETERMINATION)

Zeta potential is a vital measure for deciding the best circumstances for the steadiness of colloidal or scattered frameworks. The delivered nanoparticle suspension was inspected for zeta potential utilizing a zeta expected analyzer (Malvern Zeta seizer).Zeta potential is an electrical charge that forms an electrical barrier on the surface of a particle, and it is crucial for the stability of drugs. On the surface properties of the nanoparticle, the impact of polyvinyl alcohol and -cyclodextrin was investigated.

pH & PHYSICAL APPERANCE:

Using a pH metre, the pH of the formulation was determined. It is essential to the stability and formulation processes. Examining the formulation's external characteristics, such as colour and any suspended foreign particles, was necessary.

STABILITY STUDIES OF NANO-PARTICLES

The formulation is seen during stability testing of nanoparticles at accelerated conditions of 45 ℃ and 70% relative humidity, as well as at 4 ℃ in the refrigerator and at ambient temperature. The formulations were stored at both temperatures for three months, and enough samples were collected at regular intervals to conduct the subsequent assays.

DRUG RELEASE KINETICS STUDIES

For the evaluation of release kinetic studies, a graphical analysis was used to the improved formulation.

ZERO ORDER PLOT

The zero-request plot made by looking at the total level of drug discharge after some time.

HIGUCHI PLOT

Plotting cumulative percentage (%) drug release vs square root of time produced the Higuchi graphic.

KORESMEYER PLOT

The graph was created by plotting the cumulative percent medication release (%) against the log of time.

FIRST ORDER KINETIC RELEASE STUDY

By diagramming the log staying combined rate drug discharge versus time, the main request plots were produced.

RESULTS AND DISCUSSION

DEVELOPMENT OF AZILSARTAN NANO-PARTICLES[37, 44]

The process of nanoprecipitation was used to create all batches of nanoparticles. The needed amount of medication and polymer were both dissolved in 3 ml of ethanol before being combined with the addition of -cyclodextrin. The last volume of the planning was 10ml after the mixer had been homogenised in a vortex mixture for 1 minute. This preparation kept in a centrifuge about 30 minutes at 15000 rpm and at a temperature of 40^0C. The precipitate is washed three times with distilled water after the supernatant was discarded. The resulting nanoparticles were desiccated after being dried in an oven at 600^0C for the whole night.

A few physiochemical properties of nanoparticles, including molecule size assurance and medication discharge profile, were inspected, and the dependability of the streamlined plan at different temperatures was surveyed. Details with differed polymer proportions were made.

DRUG AND POLYMER COMPATABILITY STUDIES BY FT-IR

The compatability between the drug and polymers were identified by using FT-IR study and the drug is subjected to KBr pellet method (with a Perkin Elmer). In a hydraulic press, they are squeezed to create a clear pellet at a pressure of 15 tonnes. The pellet underwent scanning peaks were obtained by using a spectrophotometer to measure wavelengths from 4000-400cm-1.





TABLE 2: IR Spectra Data for Pure Azilsartan

Wave no. (cm^{-1})	Group Assigned
1730.21	C=O – Stretching
1408.06	C=C – Stretching
1099.46	C-N - Stretching

TABLE 3: I.R SPCTERA DATA FOR PHYSICAL MIXTURE

Wave no.(cm^{-1})	Group Assigned
1734.01	C=O – Stretching
1409.06	C=C – Stretching
1099.43	C-N - Stretching

REPORT:

The actual blend's pinnacle FTIR spectra were contrasted with the first spectra. The way that similar pinnacles were seen recommends that the medicine and the polymer didn't communicate at the sub-atomic level.

ENTRAPMENT EFFICIENCY OF NANOPARTICLES[31, 72]

Azilsartan nanoparticles entrapment efficiency was evaluated using the nano-precipitation technique. The formulation F1 (Azilsartan 50 mg with 25 mg of Polyvinyl alcohol and -cyclodextrin) has a lower entrapment value of 60.16%; this might be because the drug and polymer have a strong repulsive attraction to one another.

Table No: 4 Entrapment efficiency of Azilsartan nanoparticles

Formulation code	Drug (mg)	Poly vinyl alcohol (mg)	B cyclodextrin (mg)	Ethanol	Entrapment Efficiency (%)
NP-F1	50	25	5	2%	60.17±0.12
NP-F2	50	50	5	2%	64.25±0.16
NP-F3	50	75	5	2%	68.38±0.14
NP-F4	50	100	5	2%	73.14±0.08
NP-F5	50	25	10	2%	87.34±0.11
NP-F6	50	50	10	2%	94.36±0.16
NP-F7	50	75	10	2%	99.37±0.09
NP-F8	50	100	10	2%	87.32±0.08
NP-F9	50	25	15	2%	85.36±0.07
NP-F10	50	50	15	2%	81.26±0.01

Azilsartan 50 mg in blend with 50 mg of polyvinyl liquor and 5 mg of β - cyclodextrin in specifying F2, displayed about a higher polymer center and a higher ensnarement effectiveness of 64.15 percent. entanglement effectiveness of was 68.28% not enduring a further extension in that frame of mind in specifying F3 (Azilsartan 50 mg with 75 mg of Polyvinyl liquor and 5 mg of - cyclodextrin). Entrapment efficiency was 71.12% no matter what a further development in polymer content in specifying F4 (Azilsartan 50 mg with 100 mg of Polyvinyl liquor and 5 mg - cyclodextrin).

Subtleties F5 and F6 were made including comparable system as earlier plans, but with different polymer groupings of 25 mg, 50 mg, and 50 mg of azilsartan and 10 mg of cyclodextrin. The ampleness of not completely settled to be F5, 87.23% for F6, 94.26%.

The capture productivity of definition F7 was raised to 99.37% by expanding the polymer content while keeping different fixings the equivalent (Azilsartan 50 mg with 75 mg of Polyvinyl alcohol and 10 mg - cyclodextrin).

Growing the estimation achieved definition F8, which had an entrapment reasonability of 87.42% (Azilsartan 50 mg with 100 mg of Polyvinyl liquor and 10 mg - cyclodextrin), yet had a lower invitro appearance of the drug than itemizing F7. Thusly, the F7 definition was improved, and further investigation was done.

Azilsartan 50 mg with 25 and 50 mg of polyvinyl liquor and 15 mg of cyclodextrin were joined to make the subsequent arrangements F9 and F10. The ensnarement capability is F9 85.35% and F10 82.25%. Itemizing F7 has the best degree of snare efficiency, at 99.38%, as shown by the results above. Accordingly, this specifying was improved, and further assessment was done.

In F1, F2, F3, and F4 formulations, the entrapment efficiency reaches a limit when the polymer concentration is increased. Using 5 mg of cyclodextrin in the nanoparticles resulted in less trapping.

Hence, the formulations F5, F6, and F7 include more -cyclodextrin. (Azilsartan 50 mg with 25 mg, 50 mg, 75 mg of polyvinyl alcohol and 10 mg cyclodextrin). The entrapment efficiency in these formulations was F5 for 88.23%, F6 for 94.26%, and F7 for 99.38%. The best trapping efficiency in this was discovered in F7. Increase the amount of -cyclodextrin in formulations F8, F9, and F10 even more. Moreover, trapping effectiveness fell.

IN-VITRO DRUG RELEASE PROFILE OF NANOPARTICLES

Azilsartan nanoparticles might be delivered intravitreally for as long as 24 hours utilizing the film dispersion approach. Azilsartan nanoparticles containing polyvinyl liquor and cyclodextrin for in-vitrodrug discharge. The in-vitrodrug arrival of detailing F1 (50 mg of Azilsartan joined with 5 mg of polyvinyl liquor) At 9 hours, 97% of the medication was delivered in vitro. By expanding the polymer content (Azilsartan 50 mg with 50 mg of Polyvinyl liquor and 5 mg of - cyclodextrin), the detailing F2 was made. Following 11 hours, 96.40% of the in-vitro drug discharge was found. Further raising the polymer content was finished utilizing detailing F3 (Azilsartan 50 mg with 75 mg of Polyvinyl liquor and 5 mg - cyclodextrin). Following 13 hours, 98.44% of the drug was found to have been delivered.

Azilsartan 50 mg was mixed with 100 mg of polyvinyl liquor and 5 mg of cyclodextrin to make detailing F4 by additional rising the polymer content. Following 16 hours, 96.2% of the prescription was affirmed to have been delivered. Azilsartan 50 mg was joined with 50 mg of polyvinyl liquor and 10 mg of cyclodextrin to make definition F6, which had a higher convergence of polymer. 94.42% of the medicine was viewed as delivered in 24 hours as a rate.

Azilsartan 50 mg, polyvinyl liquor 75 mg, and cyclodextrin 10 mg were joined to make the arrangement F7. Following 24 hours, 98.46% of the medication was conveyed, it was found. Azilsartan 50 mg was gotten together with 100 mg of polyvinyl liquor and 5 mg of cyclodextrin to make arrangement F8, and the resultant degree of prescription not permanently set up to be 88% in 24 hours. Azilsartan 50 mg was gotten together with 25 gm of polyvinyl liquor and 15 mg of cyclodextrin in the enumerating F9, and the degree of drug release was represented to be 95% following 14 hours. The arrangement F10 was made by combining an updated polymer center (Azilsartan 50 mg with 50 mg Polyvinyl liquor and 15 mg - cyclodextrin) and the degree of medicine not altogether firmly established to be 96.4% following 17 hours.

When contrasted with the recently expressed plans, definition F7's level of medication discharge was brilliant and proposes a more significant level of prescription appearance of 98% for 24 hours (F1-F10). Thus, it was chosen as the best plan. At the point when the polymer focus was expanded, the in-vitro drug discharge rose in the medicine to polymer extent up to 1:1.5. The in-vitro drug discharge expanded yet didn't endure as long as 24 hours when the polymer fixation was additionally brought up in the F8 plan. Subsequently, F7 was picked as the ideal plan.

Comparative *In-vitro* Delivery Investigation Of Azilsartan Nanoparticles F1 To F10
Figure: 3



SCANNING ELECTRON MICROSCOPY [11, 26]

SEM investigation was utilized to analyze the surface properties of ideal definition (F7) molecule size. The covering of polymer blend on drug particles is found in the SEM picture of the created nanoparticle detailing. With an examining electron magnifying instrument, nanoparticles show up as granules, demonstrating a slim and in any event, covering over the prescription. In this F7 Plan, a SEM examine showed that the azilsartan nanoparticles were smooth, circular, and in the nano size range.



Fig. No:4 SEM IMAGE OF F7 SURFACE CHARGE (ZETA POTENTIAL)[19,42,25]

The surface charge property of nanoparticles is often described using the zeta capability of a nanoparticle. It mirrors the electrical capability of the particles, which is impacted by the cosmetics of the particles and the scattering medium. When nanoparticle formulations are delivered intravenously, phagocytes may quickly recognise and identify them. The adsorption of opsonins, which are blood components (proteins), is determined by the particle size and hydrophobicity of the nanoparticles' surface. The destiny of the nanoparticles is ultimately determined by the opsonin. Opsonization is the term used to describe the binding of these opsonins to the surface. Nanoparticles that were not changed opsoniazed quickly and were readily excreted from the body. Subsequently, to decrease opsoniazation and extend the nanoparticle flow in vivo. The nanoparticle plan with poly vinyl alcohol (definition F7) has a zeta capability of 38 mv, a zeta Deviation of 9.16 mV, and a conductivity of 0.899. The plan's particles are de-accumulated and remain something similar and more steady in the material. Thus, this polymer is more appropriate for making nanoparticles, and the completed item has a smooth surface, a powerful ghastly activity, and decreases

opsoniazation.

Kinetic of drug release of first order for optimized formulation F7

The graphic treatment for drug release kinetics presented the improved formulation F7.



Fig.No.5: First order plot for formulation F7
Regression = 0.7813

According to an in-vitrodischarge engine assessment, the better definition F7 of nano particles is more fitting for parenteral association. By graphing the log remaining joined rate drug release versus time, the principal demand plots were made. 0.7813 is the backslide coefficient.

CONCLUSION

The objective of the ongoing work was to make a polymer-based nanoparticulate drug conveyance framework for the hypertension medicine Azilsartan (poly vinyl liquor). With a delayed arrival of the medicine, the polymer works on the limiting of azilsartan nanoparticles to a designated or specific spot, helping restorative viability. These nanoparticles could diminish the dosing recurrence while as yet delivering the necessary helpful outcome. All nanoparticle groups (F1-F10) were made utilizing the nano precipitation procedure.

The changed arrangement F7 (drug 50 mg, polyvinyl liquor 75 mg, - cyclodextin 10 mg) had a 99.38 0.08 entrapment capability, while the invitro drug release was 98.46% following 24 hours. Furthermore, it adheres to the spread and crumbling release parts and submits to the zero solicitation. The surface morphology of the predominant definition (F7) showed that the lrbesartan not entirely settled to be in the ideal nanometer range, with a typical size of 358.4 nm.

The formulation (F7) exhibited no character changes, according to the stability test that was conducted. Zeta potential measurements were also looked at for the improved formulation (F7). The formulation (F7) had a maximum variation of 9.16 mV, indicating that the particles are distinct and that their highly repulsive nature is more effective at reducing opsonization and promoting target specificity. The created formulation of azilsartan nanoparticles enhances the drug's bioavailability, decreases dosage frequency, and boosts water solubility.

References

1. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc Chem Res, 2000; 3(6):94-101.
2. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEG-ylated systems. Pharmazie, 2002; 5(7):5-29.
3. Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor- selective gene delivery. Technol Cancer Res Treat, 2005; 4(8):15-25.
4. Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res, 2005; 9(22):1-10.
5. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release, 2002; 7(8):15-24.
6. Panyam J, Labhasetwar V. Biodegradable

nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 2003; 5(5):29-47.
7. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon G L, The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res, 1997; 1(4):68-73.
8. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res, 1996; 1(3):38-45.
9. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 2000; 2(1):1659- 1668.
10. Muller RH, Wallis KH. Surface modification of I.V. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm, 1993; 8(9):25-31.